Healthcare / BiotechnologyKOSDAQ
$3255.00
-205.00 (-5.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-3.0B · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-55.4%
↓Gross Margin
23.0%
↓Debt/Equity
0.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.2%
FCF CAGR
—
FCF margin
-13.1%
FCF / Net income
0.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $23.15B · net income $-9.13B · FCF $-3.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $23.15B | $23.15B | $23.83B | $30.13B | $35.43B |
| Net Income | $-9.13B | $-9.13B | $-3.98B | $2.00B | $6.24B |
| EBITDA | $-4.32B | $-4.32B | $-2.18B | $4.09B | $9.34B |
| EPS | -1877.00 | -1877.00 | -820.00 | 426.00 | 1511.00 |
| Gross Margin | 23.0% | 23.0% | 23.9% | 31.7% | 39.4% |
| Operating Margin | -27.1% | -27.1% | -21.5% | 4.3% | 18.0% |
| Net Margin | -39.4% | -39.4% | -16.7% | 6.6% | 17.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.72 | 0.72 | 0.31 | 0.26 | 0.47 |
| Current Ratio | 0.59 | 0.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.03B | $-3.03B | $-1.14B | $-3.02B | $-2.26B |
| Returns | |||||
| ROE | -55.4% | -55.4% | -14.4% | 5.9% | 34.8% |
| Valuation | |||||
| P/E | — | — | — | 28.59 | — |
| EV/EBITDA | — | — | — | 13.56 | — |
| P/B | 0.96 | 0.96 | 1.17 | 1.68 | — |
| Growth & Yield | |||||
| Revenue Growth | -2.9% | -2.9% | -20.9% | -15.0% | — |
| EPS Growth | -128.9% | -128.9% | -292.5% | -71.8% | — |
| Dividend Yield | 9.2% | 9.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-820.00 → -1877.00
Residual
-46.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.